Risk factors for acquisition of multidrug-resistant Enterobacterales among international travellers: A synthesis of cumulative evidence by Furuya-Kanamori, L. et al.
© International Society of Travel Medicine 2019. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.




Risk factors for acquisition of multidrug-resistant
Enterobacterales among international travellers:
a synthesis of cumulative evidence
Luis Furuya-Kanamori1,*, Jennifer Stone1, Laith Yakob2, Martyn Kirk1,
Peter Collignon3,4, Deborah J Mills5,† and Colleen L Lau1,5,†
1Research School of Population Health, ANU College of Health and Medicine, Australian National University, Canberra,
Australia, 2Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK, 3ACT Pathology,
Canberra Hospital, Canberra, Australia, 4ANU Medical School, ANU College of Health and Medicine, Australian National
University, Canberra, Australia, and 5Travel Medicine Alliance Clinics, Brisbane, Australia
∗To whom correspondence should be addressed. Email: luis.furuya-kanamori@anu.edu.au
†These authors contributed equally to this work
Submitted 29 August 2019; Revised 13 October 2019; Editorial Decision 21 October 2019; Accepted 21 October 2019
Abstract
Background: Recent studies have shown that over 50% of people travelling to Southeast Asia return colonized with
multidrug-resistant Enterobacterales (MRE) including carbapenemase-producing Enterobacterales. Importation of
MRE by travellers and subsequent spread to family members, communities and healthcare facilities poses real
risks that have not yet been adequately assessed. This systematic review and meta-analysis aims to quantify the
risk factors and interventions for reducing the risk of MRE acquisition among international travellers.
Methods: A systematic search was conducted in PubMed, Web of Science and Scopus for analytical epidemiological
studies containing data post-2000 that assessed the risk factors to acquire and/or interventions to reduce the
risk of MRE acquisition in travellers. Two researchers independently screened all the studies and extracted the
information, and disagreements were resolved through consensus. The proportions of MRE acquisition by the
region of destination and the odds ratio (OR) for the different risk factors and/or interventions were pooled using
the inverse variance heterogeneity model.
Results: A total of 20 studies (5253 travellers from high-income countries) were included in the meta-analysis.
South Asia [58.7%; 95% confidence interval (CI), 44.5–72.5%] and Northern Africa (43.9%; 95% CI 37.6–50.3%) were
the travel destinations with the highest proportion of MRE acquisition. Inflammatory bowel disease (OR 2.1; 95% CI
1.2–3.8), use of antibiotics (OR 2.4; 95% CI 1.9–3.0), traveller’s diarrhoea (OR 1.7; 95% CI 1.3–2.3) and contact with the
healthcare system overseas (OR 1.5; 95% CI 1.1–2.2) were associated with MRE colonization. Vegetarians (OR 1.4;
95% CI 1.0–2.0) and backpackers (OR 1.5; 95% CI 1.2–1.8) were also at increased odds of MRE colonization. Few studies
(n = 6) investigated preventive measures and found that consuming only bottled water/beverages, meticulous hand
hygiene and probiotics had no protective effect on MRE colonization.
Conclusions: International travel is an important driver for MRE spread worldwide. Future research needs to identify
effective interventions to reduce the risk of MRE acquisition as well as design strategies to reduce local transmission
on return.
Registration: PROSPERO CRD42018076853.
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Introduction
There is a large clinical and public health burden associated with
antimicrobial resistance (AMR) in bacteria causing human infec-
tions. This burden is increasing over time and urgent action is
required.1,2 In a report commissioned by the UK Prime Minister,
it was estimated that globally AMR could lead to 10 million
excess deaths per year and a cumulative cost of US$100 trillion
by 2050.3 The problem of AMR is much more pronounced
in low-income countries with poor water quality and sani-
tation, uncontrolled use of antibiotics, inadequate infrastruc-
ture and poor governance (i.e. corruption) all being important
contributers.4,5
Although carriage of multidrug-resistant Enterobacterales
(MRE) is much more prevalent in communities in low-income
countries (mainly in Southeast Asia, Western Pacific and Eastern
Mediterranean regions),6 high-income countries are not immune
to this problem7 (particularly in hospitals and long-term care
facilities where there is high prevalence of MRE), and multi-
resistant bacteria may also spread from country to country.8
Global trade of food (including live animals) and international
travel play major roles in the spread and transmission of resistant
organisms.9 The number of persons crossing international
borders has continued to increase over many decades, which
has provided an important opportunity for dissemination of
MRE to other countries. Asymptomatic carriers can transport
MRE between countries in their gut at alarming rates, e.g.
studies have found that 89% of travellers returning from
India and Sri Lanka to the UK were MRE carriers.10 These
travellers, including medical tourists,11 can transmit organisms to
household contacts12,13 and may introduce the organisms into the
community,14 healthcare facilities15 and the environment. Once
established, these resistant organisms are extremely expensive
and difficult to control.
In addition to the public health perspective of the risk of
introduction of multidrug-resistant pathogens, special clinical
considerations should be taken with returning travellers who are
carriers of MRE. For example, studies have reported an associ-
ation between international travellers and extended-spectrum β-
lactamase-producing (ESBL) Escherichia coli bacteraemia post
trans-rectal ultrasound guided prostate biopsy16,17 raising the
question of the role of screening and antibiotic prophylaxis in
this group of patients.
In 2015, Hassing et al. conducted a systematic review that
compiled the evidence of MRE detection among international
travellers.18 However, they did not quantitatively analyse the
data. Additionally, since the publication of the systematic review,
findings from the COMBAT study,13 the largest study on MRE
in travellers with over 2000 participants, have been published. In
this systematic review and meta-analysis, we update the evidence
by including the most recent studies and quantifying the risk
factors for MRE colonization among international travellers.
Methods
The protocol was prospectively registered in PROSPERO
(CRD42018076853), and the findings of this systematic review
and meta-analysis are presented according to PRISMA reporting
guidelines.19
Search strategy and selection criteria
The original search strategy was designed in PubMed and con-
verted for use in Web of Science and Scopus. The search included
all articles published from 2000 until February 2019, and the
search was updated in July 2019. Search terms related to ‘travel’,
‘Enterobacteriaceae’ and ‘drug resistance’ were included. To
achieve a comprehensive evaluation of the published evidence,
the systematic search was supplemented with a forwards and
backwards citation search as well as retrieving the first 20 similar
articles from PubMed for each of the studies included from the
initial search. In addition, all references from relevant previ-
ous systematic reviews were hand searched to identify possible
missed studies.
Eligible studies were analytical epidemiological studies
among international travellers that reported the rate or risk (and
protective) factors (i.e. compared MRE carriers vs non-carriers)
for MRE acquisition (e.g. due to contaminated food), coloniza-
tion (e.g. due to an underlying condition such as inflammatory
bowel disease) or selection (due to use of antibiotics) on return,
where data were available in an extractable format. Among
the risk factors of interest were demographic characteristics,
travel characteristics, past medical history, medication use and
medical problems while overseas, food exposure and reason for
travel. Potential protective factors included vaccines, probiotics
and hand hygiene. MRE included ESBL, AmpC β-lactamase
or carbapenemase-producing Enterobacterales. For a study to
be included, it must have reported the country/region of travel
and screened all participants on return for MRE and not just
targeting symptomatic participants (e.g. with diarrhoea or fever
on return). Given that the aim of the review was to describe the
current situation of MRE among international travellers, only
studies containing data post-2000 were included.
Studies reporting MRE acquisition among military personnel,
refugees and asylum seekers, adoptees, travellers seeking med-
ical attention, international inpatient transfers or during mass
gatherings (e.g. Hajj and Olympic games) were not included as
these travellers were considered at higher risk and not deemed
representative of the average traveller. Exclusion criteria also
included studies conducted on animals, in vitro studies, confer-
ence abstracts or proceedings, descriptive studies (e.g. case series)
and ecological studies. No language restriction was imposed.
Study selection and data extraction
Titles and abstracts of all papers were extracted and uploaded
to the Rayyan platform (http://rayyan.qcri.org/)20 for screening.
Two authors (LFK and JS) independently screened the titles and
abstracts on the Rayyan platform. The same authors examined
the full-text papers for eligibility in accordance with the review
protocol. Any disagreements were resolved through consensus.
Data from the included studies were extracted and sum-
marized in a spreadsheet, and the recorded fields included (i)
first author and year of publication; (ii) country and study
setting; (iii) study population characteristics (e.g. mean/median
age, proportion of females and number of travellers); (iv) travel
characteristics (e.g. travel destination and duration of travel);
(v) rate of MRE detection (i.e. number of travellers that tested
positive for MRE on return among the number of travellers that
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factors for MRE acquisition, colonization or selection; and (vii)
MRE isolate characteristics (e.g. type of bacteria and resistance
genes). Adjusted effect estimates and 95% confidence intervals
(CIs) of the risk factors were extracted. If adjusted effect esti-
mates were not available, unadjusted estimates were extracted
or computed based on the sample size and number of events (i.e.
MRE post-travel) in the exposed and unexposed groups.
Statistical analysis
Two effect measures of interest were examined, the proportion
of MRE detected and the odds ratio (OR) for risk factors.
Previous reviews18,21,22 have reported large heterogeneity in the
proportion of detection across studies, suggesting the absence of
a common worldwide effect estimate for the proportion of MRE
detection. Countries were grouped into geographical regions [i.e.
South Asia, Asia (excluding countries in South Asia), Northern
Africa, sub-Saharan Africa, South and Central America, North
America, Europe and Oceania] as in a previous systematic review
by Hassing et al.18 The detailed list of countries per region
can be found in the supplementary material (S1) (available as
Supplementary data at JTM online). A meta-regression was fitted
to examine if region of destination was a predictor for the
observed heterogeneity. It was found that region of destination
was the best predictor (accounted for over 45% of the observed
variance) of MRE detection. Therefore, the proportions of MRE
detection were pooled by the region of destination using the
inverse variance heterogeneity (IVhet) model.23 Adjusted and
unadjusted (when adjusted were not available) estimates along
with their 95% CIs were pooled for the different risk factors
using the IVhet model. The secondary objective of the systematic
review was to describe the most common bacteria isolated from
the travellers as well as report the distribution of resistance genes.
Proportion meta-analysis using the IVhet model was applied to
pool the data from the types of bacteria and resistance genes
in travellers. Statistical heterogeneity was assessed using the I2.
Publication bias was assessed using the Doi plot and LFK index.24
All the analyses were conducted in MetaXL version 5.3 (EpiGear
Int Pty Ltd; Sunrise Beach; Australia; http://www.epigear.com).
Results
Studies identified
The search identified 725 publications; 177 articles remained
after the title and abstract screening. Full-text review of 177
publications was conducted, and 28 met the eligibility criteria.
It was noted that there was overlap in participants in five
sets of publications. Four13,25–27 and two28,29 publications used
data from the COMBAT and VOYAG-R studies, respectively.
Three publications30–32 reported results from a Finnish cohort
of travellers, two publications33,34 from a cohort of Australian
healthcare volunteers and two publications35,36 from a cohort of
Dutch travellers. Therefore, 20 datasets (from 28 publications)
with 5253 travellers were included in this meta-analysis supple-
mentary material (S2).
Characteristics of the included studies
All the studies were conducted in Europe (The Nether-
lands,12,13,35,37,38 Sweden,39–42 Switzerland,43,44 France,28,45
Germany,38,46 Finland,30 UK10 and Denmark47) except for
three that were conducted in Australia,33 Japan48,49 and the
USA.49 The median age of the participants ranged from 25
to 66 years. Overall more females (n = 3028, 57.6%) were
included in the studies. The sample size ranged from 18 to 1847
participants. The median duration of travel ranged from 7 to
45 days, with 75% of the studies having a median duration
of travel between 14 and 21 days. Thirteen studies collected
stool samples,10,13,28,30,35,38–40,42,43,46,48,49 five studies used rectal
swabs12,33,41,44,45 and two studies used a combination of both
types of samples.37,47 Collection of the post-travel sample was
done within 1 month after return in 70% of the studies. The
majority of studies (n = 19, 95%) used selective media for MRE
detection that were mainly followed by genotyping confirmation,
while one study only used meta-genomic approach for MRE
detection35 (Table 1).
Quantitative analysis
Proportion of MRE detection by region of destination. Overall, there
was a wide variability in the proportion of MRE detected,
ranging from 13% to 88% and considerable heterogeneity across
studies was observed. Heterogeneity substantially decreased
when estimates were pooled by regions. South Asia (58.7%;
95% CI 44.5–72.5%), Northern Africa (43.9%; 95% CI 37.6–
50.3%) and Asia (37.5%; 95% CI 23.6–51.9%) were the travel
destinations with the highest proportion of MRE detection.
These regions were followed by sub-Saharan Africa (21.8%;
95% CI 12.0–32.4%), South and Central America (18.3%;
95% CI 8.8–28.9%) and North America (16.9%; 95% CI 2.6–
35%); while the lowest proportion of detection were observed in
Europe (10.3%; 95% CI 5.5–16.1%) and Oceania (6.9%; 95%
CI 0–21.1%) (Figure 1).
Risk factors. MRE detection was not associated with sex, age or
duration of travel, but it was dependent on the travel destination.
In terms of past medical history, it was found that inflammatory
bowel disease (OR 2.1; 95% CI 1.2–3.8) was a significant risk
factor for MRE colonization. While overseas, use of antibi-
otics (OR 2.4; 95% CI 1.9–3.0) was the strongest risk factor;
antimalarial prophylaxis (OR 1.0; 95% CI 0.8–1.4) was not
associated with MRE colonization, but it should be noted that
commonly used antimalarial medications include doxycycline (a
broad spectrum antibiotic) as well as other medications (e.g.
mefloquine, atovaquone/proguanil, chloroquine) that would not
be expected to have an effect on selection of AMR Enterobac-
terales. Other factors associated with MRE colonization were
experiencing traveller’s diarrhoea (OR 1.7; 95% CI 1.3–2.3) and
having contact with the healthcare system either as inpatients
or outpatients (OR 1.5; 95% CI 1.1–2.2). With regards to food
exposure, having a vegetarian diet (OR 1.4; 95% CI 1.0–2.0) was
found to increase the odds of acquiring MRE compared to other
diets, and consuming only bottled water/beverages did not have
an impact on MRE colonization. Among the interventions that
were examined for their potential impact in decreasing the risk
of MRE colonization, meticulous (as defined by primary study
authors) hand hygiene and probiotics had no effect, while oral
cholera vaccine (OR 1.6; 95% CI 1.0–2.5) was found to increase
the odds of MRE colonization, possible due to confounding
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Figure 1. Proportion of acquisition of MRE by region of destination.
(OR 1.5; 95% CI 1.2–1.8) increased odds of acquiring MRE
compared to other types of travellers (Table 2).
Aetiology and resistance genes. Of the 2276 MRE isolates, the vast
majority was E. coli (92.0%; 95% CI 84.9–97.3%) followed
by Klebsiella pneumoniae (5.9%; 95% CI 1.2–11.8%). The
remaining 2% of isolates included Citrobacter spp. (freundii and
amalonaticus), Proteus spp. (vulgaris and mirabilis), Enterobac-
ter cloacae, Enterococcus faecium), Acinetobacter baumannii,
Morganella morganii and a case of non-Typhi Salmonella enter-
ica.
blaCTX-M (92.3%; 95% CI 44.6–100%) was the most fre-
quent resistance gene found in the MRE isolates. CTX-M group
1 was the most common followed by CTX-M Groups 9 and 4.
blaSHV and blaTEM were found in 3.0% (95% CI 0–2.0%) and
2.0% (95% CI 0–1.8%) of the isolates, respectively. Enterobac-
terales with carbapenem- (blaOXA28,37,45 and blaNDM28,44,45) and
colistin- (mcr48) resistance genes were also isolated. A total of 50
isolates with carbapenem-resistant genes were identified mainly
from travellers returning from Southeast Asia and the Indian
subcontinent,28,37,44,45 while the 3 isolates with colistin-resistant
genes were from travellers returning from Vietnam.48
Discussion
In this systematic review and meta-analysis, we compiled data
from 20 different studies with over 5000 travellers to update the
evidence on the proportion and risk factors for MRE detection
in international travellers. The highest proportions of MRE
detection were observed from travellers returning from South
Asia, Northern Africa, Asia, sub-Saharan Africa and South and
Central America; our findings correspond with the global epi-
demiology of AMR4 and the ESBL-producing Enterobacterales
colonization prevalence among healthy individuals.50 In a meta-
analysis by Karanika et al., international travellers were found
to be four times more likely to be colonized by ESBL-producing
Enterobacterales than non-travellers.50 These findings highlight
the importance of international travel to low- and middle-income
countries in the global spread of MRE.51,52 In recent years, dis-
semination of emerging pathogens such as NDM-1 carbapenem-
resistant K. pneumoniae from India53 and mcr-1 colistin-resistant
E. coli from China54 were facilitated by international travel.55,56
Of concern is that our review revealed that carbapenem-28,37,44,45
and colistin48-resistant Enterobacterales are being detected in
international travellers. Investment in infrastructure to provide
access to clean water and adequate sanitation and hygiene may
reduce transmission in low- and middle-income countries,4 and
possibly reduce the global spread of AMR.
Contact with the healthcare system, traveller’s diarrhoea and
antibiotic use while travelling were strongly associated with
MRE detection. The possibility that these factors are associated
through reverse causality with MRE cannot be excluded (i.e.
MRE infection leading to contact with the healthcare system,
traveller’s diarrhoea and/or use of antibiotics). Even in the event
the observed associations are due to reverse causality, these
factors are markers for MRE detection and can be used to iden-
tify travellers at higher risk of being colonized by MRE. Among
the risk factors identified, one that travellers have control over
is antibiotic consumption; thus during pre-travel consultations,
healthcare professionals need to emphasize the use of antibiotics
only when required.
Acute diarrhoea is the most common condition affecting
travellers to South and Central Asia and the second most com-
mon among travellers worldwide.57 Therefore, priority areas of
research have been identified to generate evidence-based recom-
mendations for preventing traveller’s diarrhoea.58 In line with the
research priority areas, inflammatory bowel disease, a vegetarian
diet and backpacking were identified as host risk factors for
MRE detection. Although it was not possible to examine the
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Table 2. Risk factors for acquisition of MRE
OR (95% CI) I2 (%) Number of studies with adjusted
estimates/total number of studies
Demographic
Sex (female) 0.91 (0.80–1.03) 0 2/14
Age (per 10-year increase) 1.01 (0.97–1.06) 0 2/5
Travel-associated data
Duration of travel (per week increase) 1.02 (0.99–1.06) 0 1/5
Travel destination (reference Europe)∗ 1 NA 0/10
South Asia 1.52 (1.31–1.76) 0/19
Northern Africa 1.33 (1.25–1.43) 0/11
Asia 1.26 (1.17–1.35) 0/16
Sub-Saharan Africa 1.12 (0.99–1.28) 0/15
Americas 1.11 (1.02–1.20) 0/16
Past medical history
Inflammatory bowel disease 2.09 (1.16–3.77) 0 1/3
Chronic disease 1.01 (0.65–1.57) 57 2/5
Admitted to a hospital in the previous 3–6 months 1.79 (0.09–36.63) 68 1/2
Antibiotic use in the previous 3–12 months 1.00 (0.76–1.32) 12 3/4
Medical history while overseas
Antibiotic use 2.38 (1.88–3.00) 0 4/12
Anti-acid use 1.08 (0.59–1.97) 25 0/5
Antimalarial prophylaxis 1.04 (0.75–1.44) 10 0/3
Travellers’ diarrhoea 1.69 (1.25–2.30) 46 5/13
Contact with healthcare system 1.53 (1.09–2.15) 20 1/10
Food exposure
Vegetarian diet 1.41 (1.01–1.96) 0 0/5
Only consume bottled water/beverages 1.29 (0.50–3.34) 77 1/6
Protective factors
Oral cholera vaccine 1.61 (1.04–2.50) 0 0/2
Meticulous hand hygiene 1.10 (0.81–1.49) 0 1/4
Probiotics 1.06 (0.78–1.45) 0 0/2
Type of traveller
Backpackers 1.46 (1.20–1.78) 0 2/7
Holiday makers 0.99 (0.70–1.38) 0 0/4
Visiting friends and relatives 0.95 (0.55–1.63) 29 0/5
Business travellers 0.78 (0.46–1.30) 0 0/4
OR, odds ratio; CI, confidence interval; NA, not applicable.
∗OR obtained through meta-regression. Americas include North, Central and South America. Oceania was excluded from the analysis because too few studies (3) reported data for this
region.
current review, findings by Ruppe et al.28 indicate that use of
different classes of antibiotics has distinct effects on the risk
of MRE selection. They found that antibiotics used for malaria
prophylaxis (i.e. doxycycline) did not increase the risk of MRE
selection (OR 0.9; 95% CI 0.6–1.6), while beta-lactams were
associated with an increase in risk (OR 4.2; 95% CI 1.5–12.1).28
Non-antibiotic approaches to prevent MRE colonization
were also examined. Findings from the current review align
with a recent randomized controlled trial that found that
Lactobacillus rhamnosus GG did not reduce MRE colonization
in travellers.59 The effect of oral cholera vaccine was also
assessed, and paradoxically it was found that cholera vaccine
was associated with an increase in the risk of MRE colonization.
Considering that the oral cholera vaccine provides some
cross-protection against enterotoxigenic E. coli, one of the
most common causes of traveller’s diarrhoea, this association
may seem contradictory. The most likely explanation for the
observation is that unadjusted estimates were analysed and the
result is affected by confounding by indication, i.e. travellers
going to regions with higher risk of MRE are more likely to
receive oral cholera vaccine. In our previous study of MRE
detection in Australian travellers, those travelling to the Indian
subcontinent were more likely to receive oral cholera vaccine
than travellers going to other destinations; when the analysis
was adjusted for travel destination and traveller’s comorbidities,
the point estimate indicated a protective effect of oral cholera
vaccine against MRE colonization.60 To prevent confounding
by indication, randomized controlled trials are needed to
provide robust evidence on the effect of potentially protective
interventions.
It is clear that international travellers are a high-risk group;
over 50% of travellers returning from South Asia are asymp-
tomatic MRE carriers, and there is increasing evidence of sub-
sequent household transmission of MRE.12,13 Cases of ESBL-
producing E. coli bacteraemia have been reported after prostate
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risk factor for fluoroquinolone-resistant and ESBL-producing
E. coli infections.16,61 Therefore, the role of screening and contact
precaution of returned travellers from clinical and public health
perspectives need to be further examined.62 It is unfeasible to
screen all returning travellers, but in a healthcare setting, it may
be feasible to screen those who are planning to undergo higher-
risk medical procedures; although current evidence suggests that
ESBL-producing E. coli is less likely to spread among patients
in hospitals than other Enterobacterales species.63 Current stud-
ies on international patient transfers have shown that targeted
screening programs of high-risk patients may be a more cost-
effective strategy than mass screening,64 and contact precaution
and environmental cleaning with chlorine-based disinfectant can
prevent transmission.65 Given that prolonged MRE carriage is
uncommon, most travellers (∼90%) are culture-negative within
6 months,28,33,46 strategies should aim to reduce transmission and
avoid elective surgical interventions within this period.
The findings of our systematic review and meta-analysis
should be understood in light of some of the limitations.
Estimates extracted and synthesized from observational studies
included adjusted as well as unadjusted estimates; thus pooled
estimates may be affected by confounding variables. This may be
the case of potential protective interventions, where paradoxical
findings were observed. To examine regional and within-country
differences in MRE detection, as well as the risk of different
antibiotic classes and doses, more granular data are required.
Individual patient data meta-analysis may provide valuable
information to answer these questions. The current review
examined the risk factors relevant to average travellers from
high-income countries; thus findings may not be applicable to
special groups of travellers such as military personnel, refugees
and asylum seekers or hospital transfers as they may have
different risk profiles. The median age of travellers in the
included studies ranged from 25 to 66 years, so findings may not
be generalizable to children. Some studies collected post-travel
samples between 3 and 12 months post travel; thus we cannot
rule out the possibility that the participants became colonized
after their return.
In conclusion, international travel is an important driver for
MRE spread worldwide. South Asia as a travel destination is a
major risk factor for MRE acquisition. Additional risk factors
for individuals to become colonized include inflammatory bowel
disease, use of antibiotics, traveller’s diarrhoea, contact with the
healthcare system, having a vegetarian diet and backpacking.
Future research needs to identify effective interventions to reduce
the risk of MRE colonization and design strategies to reduce local
transmission on return, including transmission to household and
community members, as well as wider dissemination into the
environment and animal populations.
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Supplementary data are available at JTM online.
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